NCT00345293

Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer

A Phase I/II Study of Autologous Dendritic Cells Pulsed With Apoptotic Tumor Cells (DC/PC3) Administered Subcutaneously to Prostate Cancer Patients.

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Rockefeller University · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and activity of DC/PC3, a dendritic cell vaccine used as immunotherapy for prostate cancer. The vaccine is made with each participants' own immune cells obtained through blood donation. Dendritic cells are known to activate other immune cells such as T cells, that are able to mount an attack against cancer cells. The dendritic cell vaccine will be administered as injections every 2 weeks over a course of 2 months.

Detailed description

See Brief Summary.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
BIOLOGICAL	autologous dendritic cell vaccine (DC/PC3)	ex vivo generated autologous dendritic cells pulsed with apoptotic PC3 cells and pulsed with apoptotic PC3-M1 cells(control apoptotic cells) and pulsed with KLH (control antigen). maximum dose of DC/PC3 that we are able to generate from their initial leukaphereses product, up to a maximum of 10 x 106 DCs. Doses in the range of 105 to 10 x 106 DCs have been used clinically without toxicity

Timeline

• Start date: 2006-06-01
• Primary completion: 2013-12-01
• Completion: 2015-03-01
• First posted: 2006-06-28
• Last updated: 2016-04-18
• Results posted: 2016-04-18

Locations

1 site across 1 country: United States